Abstract 106P
Background
Colon cancer-associated transcript 1 (CCAT-1) is an oncogenic lncRNA that has been emerged as a vital biomarker for diagnosis, prognosis and therapeutic interventions in multiple malignancies. The previous studies showed that lncRNA-CCAT1 was upregulated in NSCLC cells and its expression was related to tumor growth and reduced survival rate. The aim of our study was to evaluate influence of the knockout of lncRNA-CCAT1 with the use of CRISPR-Cas9 system and G7 PAMAM dendrimers on apoptosis and proliferations of NSCLC cells.
Methods
We used two human lung adenocarcinoma cell lines: A549, H1975 and H1703 squamous cell carcinoma cell line. The knockout of the lncCCAT expression was performed using the CRISPR-Cas9 system and G7 PAMAM dendrimers. We used 4 combinations of gRNAs. The apoptosis of NSCLC after lncRNA-CCAT1 knockout was estimated with the use of flow cytometry and Annexin V staining, evaluation of caspase-3/7 and measurement of mitochondrial membrane potential changes. Expression of Ki67 was measured by flow cytometry to evaluate NSCLC cells proliferation. All mentioned above parameters were evaluated 24, 48 and 72 hours after transfection. Nonparametric ANOVA tests was used for statistical analysis.
Results
We found that transfection with conjugates of G7 PAMAM dendrimers and px459 v2.0, the appropriate gRNAs (for lncCDH5-3:3 knockout), and pcDNA3.1 plasmid are downregulating expression of lncRNA-CCAT1. We confirmed that apoptosis of NSCLC was increased after transfection and cells proliferation was reduced. We also found differences in timing and intensity of biological effects when different combination of gRNAs are used in particular NSCLC cell lines.
Conclusions
The conjugates of G7 PAMAM dendrimers and px459 v2.0, the appropriate gRNAs (for lncCDH5-3:3 knockout), and pcDNA3.1 plasmid can be used for knockout of the expression of lncRNA-CCAT1. On the other hand the gRNAs shall be individually chosen for particular NSCLC cells according to their genetic mutation status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Rzeszow.
Funding
Polish Ministry for Higher Education and Science.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
96P - The Hammersmith score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden
Presenter: James Korolewicz
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Bcl-xL prevents the arginine starvation induced by PEGylated arginine deiminase (ADI-PEG20) from inducing apoptosis
Presenter: Brian Van Tine
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Cationic dendrimers as prospective vehicles of therapeutic nucleic acids into tumor cells: Approaches, advantages and challenges
Presenter: Nadezhda Knauer
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Quantitative indicators of TREC and KREC excision rings in malignant neoplasms
Presenter: Alexander Sultanbaev
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
Presenter: Gulsah Nomak
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Prediction of radiation responses in patients with locally advanced rectal cancer with a patient-derived organoid-based radiosensitivity model
Presenter: Samart Phuwapraisirisan
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Co-expression analysis of genes encoding proteasome subunits and XPO1-related proteins in the Cancer Genome Atlas (TCGA) and the Gene Tissue Expression (GTEx) databases as a tool to devise new treatment strategies
Presenter: Vito Spataro
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - Microsomal triglyceride transfer protein as a prognostic and therapeutic marker for brain cancer
Presenter: Ryuk Jun Kwon
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Choline transporter-like protein 1 is a novel molecular target for the treatment of hepatocellular carcinoma
Presenter: Masato Inazu
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Censoring imbalance in ACIS trial for prostate cancer
Presenter: Noa Zimhony-Nissim
Session: Cocktail & Poster Display session
Resources:
Abstract